Antitrust & Competition Policy Blog

Editor: D. Daniel Sokol
University of Florida
Levin College of Law

A Member of the Law Professor Blogs Network

Wednesday, June 3, 2009

Entry in the ADHD Drugs Market: Welfare Impact of Generics and Me-toos

Posted by D. Daniel Sokol

Farasat A.S. Bokhari (FSU - Econ) and Gary M. Fournier (FSU - Econ) explain Entry in the ADHD Drugs Market: Welfare Impact of Generics and Me-toos.

ABSTRACT: In this paper, we exploit a novel approach for instrumenting a di fferentiated products demand system for therapeutically equivalent drugs. Using unusually detailed sales data on psychostimulant drugs, used to treat Attention De cit Hyperactivity Disorder (ADHD), we are able to identify and measure substitution patterns across a range of drugs. We find that the demand for ADHD drugs is quite elastic and there are significant substitution possibilities among these drugs, both within the molecule and form, as well as across the segments. In addition, the first-time introduction of a generic drug shows large welfare gains due to expansion of the market to price sensitive consumers. Further, the welfare gains due to the introduction of me-too drugs vary by the novelty of the drug, and for significantly new varieties can be as large as those of the introduction of a generic. Our results bear policy implications for both, the speed with which new drugs are approved for marketing, as well as for actions among pharmaceutical firms that may delay the
entry of a generic drug.

http://lawprofessors.typepad.com/antitrustprof_blog/2009/06/entry-in-the-adhd-drugs-market-welfare-impact-of-generics-and-metoos.html

| Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef011570a46658970b

Listed below are links to weblogs that reference Entry in the ADHD Drugs Market: Welfare Impact of Generics and Me-toos:

Comments

Post a comment